Abstract
Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce. We conducted a prospective single-center study exploring the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19). Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity. While patients with prior COVID-19 showed the best response after one, SARS-CoV-2-naïve patients may benefit from a third vaccine injection.
Keywords: Cellular immune response; Hemodialysis; Immunoglobulins; Peritoneal dialysis; T cells.
【저자키워드】 Cellular immune response, T cells, immunoglobulins, Hemodialysis, Peritoneal dialysis, 【초록키워드】 COVID-19, immune response, T cells, immunization, immune, SARS-CoV-2 vaccine, dialysis, immunoassay, Humoral immunity, T cell, cellular immunity, CMIA, Patient, morbidity and mortality, ELISPOT, humoral immune response, homologous, predict, single dose, cellular, dose, Anti-spike IgG antibody, regimen, interferon-γ, seroconversion rate, single-center study, while, Microparticle, Complete, benefit, the patient, assays, conducted, receiving, vaccine injection, 【제목키워드】 immunogenicity, reactogenicity, SARS-CoV-2 vaccine, dialysis, Patient, homologous, regimen, receiving, mRNA-based,